Highnoon Laboratories Limited (HINOON): Corporate Briefing Takeaways - By Sherman Research

<p></p><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Highnoon Laboratories Limited held a corporate briefing today to discuss its CY24 financial results. Just to recall, the company reported consolidated revenue growth of 25%YoY, reaching Rs25bn in CY24 &ndash; higher than listed sector industry growth of 20%. Moreover, the company also registered highest net margin of 14% amongst listed pharma firms, beating industry average of 7%.</span></li></ul><ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Highnoon maintains a well-diversified product portfolio. The company disclosed that anti-infectives contributes major share of 25% in overall revenue, followed by the Cardiovascular segment (23%), and Alimentary (22%).</span></li></ul><ul><li><span style="font-family:Arial...